Catalent, Inc. (NYSE:CTLT) SVP Joseph Anthony Ferraro Sells 320 Shares

Catalent, Inc. (NYSE:CTLT) SVP Joseph Anthony Ferraro sold 320 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $59.97, for a total transaction of $19,190.40. Following the completion of the sale, the senior vice president now owns 23,967 shares in the company, valued at approximately $1,437,300.99. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Catalent Stock Performance

CTLT traded down $0.01 on Monday, reaching $60.28. The company had a trading volume of 344,587 shares, compared to its average volume of 2,039,350. The company’s fifty day moving average is $60.12 and its 200 day moving average is $57.79. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The stock has a market cap of $10.91 billion, a P/E ratio of -9.88, a P/E/G ratio of 2.14 and a beta of 1.15. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $61.20.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The business had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.23 billion. As a group, analysts predict that Catalent, Inc. will post 0.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Mather Group LLC. acquired a new position in shares of Catalent during the first quarter worth $52,000. Czech National Bank boosted its stake in shares of Catalent by 0.7% during the first quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after purchasing an additional 228 shares in the last quarter. Sound Income Strategies LLC grew its holdings in shares of Catalent by 4,466.7% during the first quarter. Sound Income Strategies LLC now owns 1,370 shares of the company’s stock worth $77,000 after purchasing an additional 1,340 shares during the last quarter. Norden Group LLC acquired a new position in shares of Catalent in the first quarter valued at approximately $1,222,000. Finally, Principal Financial Group Inc. boosted its position in Catalent by 1.7% during the 1st quarter. Principal Financial Group Inc. now owns 206,694 shares of the company’s stock worth $11,668,000 after buying an additional 3,499 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CTLT shares. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Barclays increased their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Finally, StockNews.com started coverage on Catalent in a report on Saturday, October 12th. They set a “hold” rating for the company. Nine research analysts have rated the stock with a hold rating, According to MarketBeat, Catalent has an average rating of “Hold” and a consensus target price of $59.83.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.